IRTC Stock Analysis: iRhythm Technologies | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 3.997m USD | 12M Return: -31% | US4500561067 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 52.1M
Qual. Beats: 2
Rev. Trend: 99.7%
Qual. Beats: 7
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
iRhythm Holdings (NASDAQ: IRTC) is a U.S. digital healthcare company that designs, develops, and commercializes device-based technology for ambulatory cardiac monitoring, primarily used to diagnose arrhythmias. The company is best known for its Zio suite of products, which are prescription-only, patch-based remote ECG monitoring systems worn continuously for up to 14 days. The portfolio includes the Zio Monitor, Zio XT, and Zio AT Systems, along with the Zio ECG Utilization Software (ZEUS), which captures and analyzes the recorded heart-signal data.
The companys business model centers on a service-plus-device approach: patients wear the adhesive Zio patch at home, the device records continuous ECG data, and iRhythms software platform analyzes the readings for physicians. This positions iRhythm in the broader digital health and wearable cardiac monitoring sector, where patch-based ambulatory monitors have largely displaced traditional 24-48 hour Holter monitors as a preferred tool for detecting intermittent arrhythmias, given their longer wear time and higher diagnostic yield. iRhythm also has a development collaboration with BioIS to incorporate additional sensing capabilities, such as pulse oximetry, accelerometry, and non-invasive blood pressure, into future ambulatory cardiac monitoring offerings.
iRhythm was incorporated in 2006, is headquartered in San Francisco, California, and went public in October 2016. The company was renamed from iRhythm Technologies, Inc. to iRhythm Holdings, Inc. in January 2026. It operates within the GICS Health Care Equipment sub-industry and is classified as a mid-cap stock.
- Zio monitor demand drives core revenue growth
- Medicare reimbursement rate decisions impact margins
- Competition from Biotricity and Philips pressures market share
| Net Income: -13.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 6.84 > 1.0 |
| NWC/Revenue: 67.90% < 20% (prev 80.90%; Δ -13.00% < -1%) |
| CFO/TA 0.08 > 3% & CFO 86.0m > Net Income -13.9m |
| Net Debt (257.3m) to EBITDA (26.9m): 9.58 < 3 |
| Current Ratio: 3.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.9m) vs 12m ago 2.83% < -2% |
| Gross Margin: 71.45% > 18% (prev 69.78%; Δ 1.67% > 0.5%) |
| Asset Turnover: 80.23% > 50% (prev 68.17%; Δ 12.05% > 0%) |
| Interest Coverage Ratio: 0.02 > 6 (EBIT TTM 211k / Interest Expense TTM 13.2m) |
| A: 0.51 (Total Current Assets 756.0m - Total Current Liabilities 195.6m) / Total Assets 1.09b |
| B: -0.75 (Retained Earnings -817.8m / Total Assets 1.09b) |
| C: 0.00 (EBIT TTM 211k / Avg Total Assets 1.03b) |
| D: 0.21 (Book Value of Equity 186.0m / Total Liabilities 906.9m) |
| Altman-Z'' = 1.14 = BB |
| DSRI: 0.82 (Receivables 84.3m/82.2m, Revenue 825.3m/657.2m) |
| GMI: 0.98 (GM 69.78% / 71.45%) |
| AQI: 1.02 (AQ_t 0.12 / AQ_t-1 0.12) |
| SGI: 1.26 (Revenue 825.3m / 657.2m) |
| TATA: -0.09 (NI -13.9m - CFO 86.0m) / TA 1.09b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of October 30, 2026, the stock is trading at USD 127.80 with a total of 550,248 shares traded. Over the past week, the price has changed by +6.82%, over one month by +11.89%, over three months by +4.38% and over the past year by -31.03%.
Current recommended Stop Loss: 122.10 (which is 4.5% or 1.3 ATR below the current price).
iRhythm Technologies has received a consensus analysts rating of 4.81. Therefore, it is recommended to buy IRTC.
- StrongBuy: 13
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 171.3 | 34.1% |
P/E Forward = 90.9091
P/S = 4.8434
P/B = 19.8151
Revenue TTM = 825.3m USD
EBIT TTM = 211k USD
EBITDA TTM = 26.9m USD
Long Term Debt = 651.1m USD (from longTermDebt, last quarter)
Short Term Debt = 18.4m USD (from shortTermDebt, last quarter)
Debt = 848.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 121.3m
Net Debt = 257.3m USD (calculated: Debt 848.6m - CCE 591.3m)
Enterprise Value = 4.25b USD (4.00b + Debt 848.6m - CCE 591.3m)
Interest Coverage Ratio = 0.02 (Ebit TTM 211k / Interest Expense TTM 13.2m)
EV/FCF = 86.28x (Enterprise Value 4.25b / FCF TTM 49.3m)
FCF Yield = 1.16% (FCF TTM 49.3m / Enterprise Value 4.25b)
FCF Margin = 5.98% (FCF TTM 49.3m / Revenue TTM 825.3m)
Net Margin = -1.69% (Net Income TTM -13.9m / Revenue TTM 825.3m)
Gross Margin = 71.45% ((Revenue TTM 825.3m - Cost of Revenue TTM 235.6m) / Revenue TTM)
Gross Margin QoQ = 72.80% (prev 70.89%)
Tobins Q-Ratio = 3.89 (Enterprise Value 4.25b / Total Assets 1.09b)
Interest Expense / Debt = 1.55% (Interest Expense 13.2m / Debt 848.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 167k (EBIT 211k * (1 - 21.00%))
Current Ratio = 3.55 (Total Current Assets 756.0m / Total Current Liabilities 213.0m)
Debt / Equity = 4.56 (Debt 848.6m / totalStockholderEquity, last quarter 186.0m)
Debt / EBITDA = 9.58 (Net Debt 257.3m / EBITDA 26.9m)
Debt / FCF = 5.22 (Net Debt 257.3m / FCF TTM 49.3m)
Total Stockholder Equity = 155.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.36% (Net Income -13.9m / Total Assets 1.09b)
RoE = -8.97% (Net Income TTM -13.9m / Total Stockholder Equity 155.5m)
RoCE = 0.03% (EBIT 211k / Capital Employed (Equity 155.5m + L.T.Debt 651.1m))
RoIC = 0.02% (NOPAT 167k / Invested Capital 875.0m)
WACC = 6.63% (E(4.00b)/V(4.85b) * Re(7.78%) + D(848.6m)/V(4.85b) * Rd(1.55%) * (1-Tc(0.21)))
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.79 | Cagr: 2.62%
[DCF] Terminal Value 75.44% ; FCFF base≈49.3m ; Y1≈49.5m ; Y5≈52.5m
[DCF] Fair Price = 16.94 (EV 815.9m - Net Debt 257.3m = Equity 558.5m / Shares 33.0m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.80 | # QB: 2
Revenue Correlation: 99.73 | Revenue CAGR: 23.08% | SUE: 1.31 | # QB: 7
EPS current Quarter (2026-09-30): EPS=0.05 | Chg30d=+10.71% | Revisions=-55% | Analysts=11
EPS current Year (2026-12-31): EPS=0.55 | Chg30d=-5.37% | Revisions=+25% | GrowthEPS=+153.7% | GrowthRev=+19.4%
EPS next Year (2027-12-31): EPS=1.25 | Chg30d=+3.61% | Revisions=+25% | GrowthEPS=+125.1% | GrowthRev=+16.6%
[Analyst] Revisions Ratio: -31% (up=3, down=7)